Aethlon Medical — Second Quarter Fiscal 2027 Earnings Summary

Aethlon Medical, Inc. reported a net loss of $2.62 million for the second quarter ended September 30, 2026, with operating expenses rising 77.2% to $2.7 million primarily due to professional fees associated with a proposed merger. On September 17, 2026, the company entered into a merger agreement with North Immunology, Inc., under which the combined entity will operate as North Immunology and shareholders will receive contingent value rights tied to the legacy Hemopurifier business. During the quarter, the company treated its second patient in the final dosing cohort of its Phase 1 oncology study in Australia and implemented workforce reductions to align with the merger timeline. As of September 30, 2026, the company held approximately $6.5 million in cash and cash equivalents.